Jarrow Formulas Methyl B-12 500 mcg - 100 Chewable Tablets, Cherry - Bioactive Vitamin B12 - Supports Energy Production, Brain Health & Metabolism - Gluten Free - 100 Servings
- Bioactive B12 - Jarrow Formulas Methyl B-12 (methylcobalamin) is the biologically active coenzyme form of vitamin B12. It supports brain and nerve health & function, energy production, cell replication, red blood cell production & sleep-wake cycles.
- Homocysteine Metabolism - Methyl B-12 is also required to metabolize homocysteine back into the essential amino acid L-methionine.
- Better Retained - Research suggests that methyl B-12 is better retained in the body than cyanocobalamin, and supplementation may be needed by some vegetarians/vegans.
- Convenient Chewable Tablet - Each cherry-flavored chewable tablet delivers 500 micrograms (mcg) of methyl B-12. Our formula contains no wheat, gluten, soybeans, dairy, egg, fish/shellfish, or peanuts/tree nuts.
- Superior Nutrition & Formulation - The goal of Jarrow Formulas is to promote optimal health with high-quality, effective, affordable, and superior formulation of dietary supplements. Our customers can be assured of purity, value, and potency.
How should vitamin B12 replacement be done?
The parenteral route is especially indicated in patients with difficulties in gastrointestinal absorption, as in the following situations: pernicious anemia, history of bariatric surgery, previous gastrectomy, Crohn's disease, celiac disease. In the elderly, atrophic gastritis and hypochlorhydria (due to prolonged use of omeprazole) reduces gastric acidity and also hinders absorption. The parenteral route, due to its fast absorption and better adherence, is also preferred in patients with symptomatic anemia, neurological or neuropsychiatric symptoms, in children and in pregnant women.
Studies have shown that the oral route is equally effective in correcting anemia and neurological symptoms in patients with good adherence, despite having a higher cost. It can be used in those asymptomatic patients with mild to moderate disabilities.
Posology Asymptomatic adults: 1000 mcg of vitamin B12, intramuscularly, once a week, until the deficiency is corrected (usually 6 to 8 weeks). Afterwards, for cases with replacement indication for life, once a month (cyanocobalamin) or once every two months (hydroxycobalamin). The 1000 mcg oral dose, once a day, is equally effective. Symptomatic: 1000 mcg of vitamin B12 every other day (every other day), for 2 weeks, followed by once a month (cyanocobalamin) or once every two months (hydroxycobalamin). Children: 50 to 100 mcg, intramuscularly, 1x / week until the deficiency is corrected. Afterwards, for cases with replacement indication for life, once a month (cyanocobalamin) or once every two months (hydroxycobalamin). Oral doses in children are not well established. Special situations Pernicious anemia (autoimmune gastritis): 1000 mcg, once a week, for 4 weeks, followed by 1000 mcg 1x month. Therapy should be continued indefinitely. Vitamin B 12 deficient diets: Individuals with vitamin B 12 deficient diets (vegans, vegetarians, babies exclusively breastfed by B 12 deficient mothers) have normal oral absorption and can be treated in this way.
Neuropsychiatric symptoms: Assess clinical improvement after 2 to 3 months of treatment. If a patient reports partial improvement, consider extending therapy monthly to 6 months after symptom improvement. Follow-up If the change is permanent (pernicious anemia, gastrectomy), treatment continues indefinitely throughout life. If the cause of the change is reversed (diet deficiency), treatment can be stopped when the deficiency is corrected. In this case, it is recommended to dose vitamin B12 in 3 to 12 months after the end of treatment. The dosage of vitamin B12 during therapy is not useful, as it increases with replacement, regardless of the effectiveness of the treatment. Monitoring must be carried out by means of a clinical response and the request for a complete blood count.
The hematological response is rapid, with an increase in reticulocytes in 1 week and correction of hematological changes in 6 to 8 weeks. The improvement of neurological signs and symptoms begins in one week, but it can take up to 6 months to resolve. In those patients who do not have a clinical or hematological response after 2 months of treatment, the level of vitamin B12 can be measured in 1 month after the end of the proposed therapy. it is recommended to dose vitamin B12 in 3 to 12 months after the end of treatment. The dosage of vitamin B12 during therapy is not useful, as it increases with replacement, regardless of the effectiveness of the treatment. Monitoring must be carried out by means of a clinical response and the request for a complete blood count. The hematological response is rapid, with an increase in reticulocytes in 1 week and correction of hematological changes in 6 to 8 weeks. The improvement of neurological signs and symptoms begins in one week, but it can take up to 6 months to resolve. In those patients who do not have a clinical or hematological response after 2 months of treatment, the level of vitamin B12 can be measured in 1 month after the end of the proposed therapy. it is recommended to dose vitamin B12 in 3 to 12 months after the end of treatment. The dosage of vitamin B12 during therapy is not useful, as it increases with replacement, regardless of the effectiveness of the treatment. Monitoring must be carried out by means of a clinical response and the request for a complete blood count. The hematological response is rapid, with an increase in reticulocytes in 1 week and correction of hematological changes in 6 to 8 weeks.
The improvement of neurological signs and symptoms begins in one week, but it can take up to 6 months to resolve. In those patients who do not have a clinical or hematological response after 2 months of treatment, the level of vitamin B12 can be measured in 1 month after the end of the proposed therapy. The dosage of vitamin B12 during therapy is not useful, as it increases with replacement, regardless of the effectiveness of the treatment. Monitoring must be carried out by means of a clinical response and the request for a complete blood count. The hematological response is rapid, with an increase in reticulocytes in 1 week and correction of hematological changes in 6 to 8 weeks.
The improvement of neurological signs and symptoms begins in one week, but it can take up to 6 months to resolve. In those patients who do not have a clinical or hematological response after 2 months of treatment, the level of vitamin B12 can be measured in 1 month after the end of the proposed therapy. The dosage of vitamin B12 during therapy is not useful, as it increases with replacement, regardless of the effectiveness of the treatment. Monitoring must be carried out by means of a clinical response and the request for a complete blood count. The hematological response is rapid, with an increase in reticulocytes in 1 week and correction of hematological changes in 6 to 8 weeks. The improvement of neurological signs and symptoms starts in one week, but it can take up to 6 months to resolve. In those patients who do not have a clinical or hematological response after 2 months of treatment, the level of vitamin B12 can be measured in 1 month after the end of the proposed therapy. The hematological response is rapid, with an increase in reticulocytes in 1 week and correction of hematological changes in 6 to 8 weeks. The improvement of neurological signs and symptoms begins in one week, but it can take up to 6 months to resolve. In those patients who do not have a clinical or hematological response after 2 months of treatment, the level of vitamin B12 can be measured in 1 month after the end of the proposed therapy.
The hematological response is rapid, with an increase in reticulocytes in 1 week and correction of hematological changes in 6 to 8 weeks. The improvement of neurological signs and symptoms starts in one week, but it can take up to 6 months to resolve. In those patients who do not have a clinical or hematological response after 2 months of treatment, the level of vitamin B12 can be measured in 1 month after the end of the proposed therapy.
